It has been over four years since Turing Pharmaceuticals AG and its founder Martin Shkreli raised the price of the antiparasitic drug Daraprim (pyrimethamine) by more than 4,000 percent, putting a spotlight on drug pricing. But the US Federal Trade Commission and New York Attorney General allege that since then they have engaged in an anticompetitive scheme to block generic competition and keep the price of the drug exorbitantly high.
On 27 January, the FTC and state of New York jointly filed a redacted complaint against [Vyera Pharmaceuticals LLC],...





